We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Health Agencies Update |

Experimental Treatment for Batten Disease Shows Promise

Bridget M. Kuehn, MSJ
JAMA. 2013;310(20):2140. doi:10.1001/jama.2013.283507.
Text Size: A A A
Published online


A compound has shown promise as a potential treatment for Batten disease, a rare neurodegenerative disorder, in cell and mice studies, according to a study funded by the Eunice Shriver Kennedy National Institute of Child Health and Human Development.

About 1 in 12 500 infants is born with a form of neuronal ceroid lipofuscinosis (NCL), which is also called Batten disease, according to the study’s authors (Sarkar C et al. Nat Neurosci. doi:10.1038/nn.3526 [published online September 22, 2013]). The disease develops when a mutation inactivates a gene that cleaves a linkage on palmitoylated proteins. This prevents lysosomal hydrolases from breaking down the proteins, causing a buildup of lysosomal ceroids, with neurotoxic effects. Children who are born with NCL develop progressive psychomotor delays by about 12 to 18 months of age. These delays progress to blindness by age 2 years, loss of most brain activity by age 4 years, and eventual death during childhood, after years in a vegetative state.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections